42 results on '"Shamai, Sivan"'
Search Results
2. The predictive value of high sensitivity troponin measurements in patients treated with immune checkpoint inhibitors
3. Abstract 12234: Concurrent Amyloid Light-Chain Cardiac Amyloidosis and Abdominal Leiomyosarcoma - Diagnostic and Therapeutic Challenges
4. The use of medical cannabis concomitantly with immune checkpoint inhibitors in non-small cell lung cancer: A sigh of relief?
5. VELOCITY-Lung substudy-03: A phase 2 study of neoadjuvant domvanalimab (dom)+zimberelimab (zim)+chemotherapy (chemo) or zim+chemo followed by adjuvant dom+zim or zim in patients with resectable stage II-III non-small cell lung cancer (NSCLC).
6. Real-World Clinical Outcomes of Neoadjuvant Platinum-Based Chemotherapy with Nivolumab in Non-Small Cell Lung Cancer.
7. COVID-19 Vaccine-Induced Radiation Recall Phenomenon
8. Severe Postoperative Complications are Associated with Impaired Survival in Primary but not in Recurrent Retroperitoneal Sarcoma
9. Eculizumab-Responsive Adult Onset Protein Losing Enteropathy, Caused by Germline CD55-Deficiency and Complicated by Aggressive Angiosarcoma
10. Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis
11. The prognostic value of beta-1 blockers in patients with non-small-cell lung carcinoma treated with pembrolizumab
12. Reply to “Metformin as a booster or obstacle of immunotherapy in patients with non–small cell lung cancer and diabetes mellitus”
13. Artificial intelligence (AI) molecular analysis tool assists in rapid treatment decision in lung cancer: a case report
14. Cardio-toxicity among patients with sarcoma: a cardio-oncology registry
15. Immune-related Neutropenia Following Treatment With Immune Checkpoint Inhibitors
16. Association between diabetes mellitus and reduced efficacy of pembrolizumab in non-small cell lung cancer
17. Association between diabetes mellitus and reduced efficacy of pembrolizumab in non–small cell lung cancer.
18. A Lymph Node Ratio Model for Prognosis of Patients with Pancreatic Neuroendocrine Tumors
19. The predictive value of high sensitivity troponin measurements in patients treated with immune checkpoint inhibitors
20. Selective Intra-Arterial Doxorubicin Eluting Microsphere Embolization for Desmoid Fibromatosis: A Combined Prospective and Retrospective Study
21. Weekly carboplatin with paclitaxel compared to standard three-weekly treatment in advanced epithelial ovarian carcinoma — a retrospective study
22. ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data
23. Is there a role for adjuvant chemotherapy in pathological complete response rectal cancer tumors following neoadjuvant chemoradiotherapy?
24. Cancer Therapeutics–related Cardiac Dysfunction in Patients Treated With Immune Checkpoint Inhibitors: An Understudied Manifestation
25. Diastolic function as an early marker for systolic dysfunction and all‐cause mortality among cancer patients
26. Eculizumab-Responsive Adult Onset Protein Losing Enteropathy, Caused by Germline CD55-Deficiency and Complicated by Aggressive Angiosarcoma
27. Severe Postoperative Complications are Associated with Impaired Survival in Primary but not in Recurrent Retroperitoneal Sarcoma
28. Innate inflammatory markers for predicting survival in retroperitoneal sarcoma
29. A phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (CKS).
30. Immune-related Neutropenia Following Treatment With Immune Checkpoint Inhibitors
31. Cardio-toxicity among patients with sarcoma: A Cardio-Oncology Registry.
32. A phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated Classic Kaposi sarcoma (CKS).
33. Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data
34. Efficacy and safety of Nivolumab in non‑small cell lung cancer patients in Tel‑Aviv tertiary medical center: Facing the reality
35. Next generation sequencing (NGS) in soft tissue / bone sarcoma (STS/BS) patients.
36. Reply to "Metformin as a booster or obstacle of immunotherapy in patients with non–small cell lung cancer and diabetes mellitus".
37. Trabectedin for advanced soft tissue sarcoma: Ten-year real-life perspective.
38. MA13.05 Nivolumab in Non-Small Cell Lung Cancer (NSCLC): The Real-Life Data
39. P3.07-004 Nivolumab for Non-Small Cell Lung Cancer (NSCLC): An Economic Model for Risk Sharing Based on Real-Life Data
40. Trabectedin for Advanced Soft Tissue Sarcoma: Ten Year Real-Life Perspective.
41. CD24 and APC Genetic Polymorphisms in Pancreatic Cancers as Potential Biomarkers for Clinical Outcome
42. The Predictive Role of ERCC1 Status in Oxaliplatin Based Neoadjuvant Therapy for Metastatic Colorectal Cancer (mCRC) to the Liver
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.